Nama's AI scorecard currently rates Privia Health Group Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PRVA's P/E ratio?

Privia Health Group trades at a trailing price-to-earnings ratio of 29.1.

When does PRVA report earnings?

Privia Health Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.25.

What is the PRVA price target?

The median analyst price target from 17 analysts is $31.00, with a range of $24.00 – $40.00.

Is PRVA Shariah compliant?

Nama's AAOIFI-style screen reads Privia Health Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Privia Health Group (PRVA)

Healthcare · Health Information Services · NASDAQ

Privia Health Group (PRVA) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $3.12B, a trailing price-to-earnings ratio of 29.1 and a free-cash-flow yield of 5.2%. Over the most recent reported fiscal year, revenue grew 22.3% and free cash flow per share grew 45.7%. Nama's AI scorecard rates it Hold, 4.7 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 4.7/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -15.3% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-45.3%

How far the last close sits under the highest price of the past five years.

Market cap	$3.12B
Trailing P/E	29.1
Price / book	4.0
Price / sales	1.3
FCF yield	5.2%
Dividend yield	—
Gross margin	10.0%
Operating margin	1.9%
Net margin	1.2%
Revenue growth (YoY)	+22.3%
Revenue growth (3-yr annual)	+16.1%
EPS growth (YoY)	+28.2%
FCF/share growth (YoY)	+45.7%
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

PRVA earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.25). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.21	$0.24	-12.5%	—
Q2 2026	Aug 6, 2026	$0.19	$0.24	-20.8%	$632.63M
Q1 2026	May 7, 2026	$0.19	$0.25	-24.0%	$603.85M
Q4 2025	Feb 26, 2026	$0.25	$0.19	+31.6%	$541.17M

PRVA analyst price target

Median target $31.00 from 17 analysts, ranging $24.00 – $40.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2

Explore live PRVA data on Nama Insights →

PRVA FAQ

Is PRVA a buy?: Nama's AI scorecard currently rates Privia Health Group Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PRVA's P/E ratio?: Privia Health Group trades at a trailing price-to-earnings ratio of 29.1.
When does PRVA report earnings?: Privia Health Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.25.
What is the PRVA price target?: The median analyst price target from 17 analysts is $31.00, with a range of $24.00 – $40.00.
Is PRVA Shariah compliant?: Nama's AAOIFI-style screen reads Privia Health Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.